FEMSelect Inc.

FEMSelect Inc. is a women's health medical device company headquartered in Newark, Delaware, with international operations in Israel, Chile, Costa Rica, Cyprus, and Mexico. The company develops and commercializes minimally invasive medical devices for the treatment of pelvic organ prolapse (POP), a condition affecting more than half of women over 50. The primary product is EnPlace, an FDA-cleared same-day, minimally invasive surgical approach for pelvic organ prolapse that typically requires no overnight hospital stay and aims to enable women to return quickly to normal activities including exercise and intimacy. The company also offers Elitone, a related pelvic health product. EnPlace is positioned as an alternative to conservative management approaches such as pessaries, physical therapy, and Kegel exercises, as well as to traditional surgical interventions. FEMSelect operates a network of trained providers across the United States and internationally through regional distribution partners. The company maintains FDA regulatory clearance for its products and serves gynecologists, urologists, urogynecologists, and other clinicians who manage pelvic floor disorders. Manufacturing and clinical trial data demonstrate human efficacy and safety. The company focuses on patient education and provider training to expand access to minimally invasive pelvic organ prolapse treatment.